Breaking News
According to multiple large observational studies, the risk of dementia is associated with eight routine adult vaccines: the shingles, respiratory syncytial virus, influenza, DTP (diphtheria, tetanus and pertussis), pneumococcal, hepatitis A, hepatitis B and typhoid vaccines.
Takeda’s pivotal Phase II/III clinical trial of its investigational TAK-881K SCIG 20% with recombinant human hyaluronidase) in patients with primary immunodeficiency met its primary and secondary endpoints.
The U.S. Food and Drug Administration has approved ADMA Biologics’ supplemental biologics license application to expand the prescribing information to primary humoral immunodeficiency indication to pediatric patients 2 years of age and older.
U.S. Representatives Adrian Smith (R-NE-03) and Doris Matsui (D-CA-07) have introduced the PI Post Acute Access Act to expand access to lifesaving care for individuals with primary immunodeficiencies
Intravenous immune globulin (IVIG) improved clinical response rates in patients with autoimmune encephalitis (AE) who had inadequate response to steroid pulse therapy.
GC Biopharma has developed a proprietary enzyme-linked immunoassay (ELISA) that effectively mitigates heterophilic antibody interference to precisely measure factor XI (FXI) levels.
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
BSTQ Podcast
Healthcare Marketplace News & Insights
The BioSupply Trends Quarterly (BSTQ) Podcast brings together healthcare professionals, researchers, innovators and advocates to explore the scientific, clinical and operational trends shaping the future of biotherapeutics, healthcare delivery and public health.
